阿托伐他汀协同阿贝西利联合氟维司群治疗HR+/HER2-型晚期乳腺癌患者的临床效果  

Clinical Efficacy of Atorvastatin in Combination with Abemaciclib and Fulvestrant in the Treatment of HR+HER2-Type Advanced Breast Cancer

作　　者：马丁丁 石鑫 左宏波 蒋轶[1] 王志[1] MA Dingding;SHI Xin;ZUO Hongbo;JIANG Yi;WANG Zhi(Department of Oncology,Jiujiang NO.1 People's Hospital,Jiujiang 332000,China)

机构地区：[1]九江市第一人民医院肿瘤科,江西九江332000

出　　处：《中国医学创新》2025年第4期10-14,共5页Medical Innovation of China

基　　金：江西省卫生健康委科技计划项目(202311458)。

摘　　要：目的:探讨阿托伐他汀协同阿贝西利联合氟维司群治疗激素受体阳性/人表皮生长因子受体2阴性(HR+/HER2-)型晚期乳腺癌患者的临床效果。方法:选取2022年1月—2023年8月九江市第一人民医院收治的75例HR+/HER2-型晚期乳腺癌患者为研究对象,将其随机分为对照组、试验A组和试验B组,每组25例。对照组给予安慰剂加阿贝西利联合氟维司群治疗,试验A组与试验B组均给予阿托伐他汀加阿贝西利联合氟维司群治疗,其中试验A组阿托伐他汀10 mg/次,试验B组阿托伐他汀20 mg/次,共治疗6个周期。比较治疗前、治疗2、4、6周期后三组的临床疗效、肿瘤标志物癌胚抗原(CEA)和乳腺癌相关抗原153(CA153)水平、血脂指标及不良反应发生情况。结果:三组临床疗效比较,差异有统计学意义(P<0.05);试验A组与试验B组临床有效率均高于对照组(P<0.05);CEA、CA153水平在时间、组间效应上差异均有统计学意义(P<0.05),且时间与组间存在交互作用(P<0.05)。治疗2、4、6个周期后,试验A组、试验B组的CEA、CA153均低于对照组,试验B组均低于试验A组,差异均有统计学意义(P<0.05)。总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平在时间、组间效应上差异均有统计学意义(P<0.05),HDL-C水平在时间与组间存在交互作用(P<0.05)。试验A组、试验B组的HDL-C水平均高于对照组,试验B组均高于试验A组,差异均有统计学意义(P<0.05)。试验B组的恶心呕吐发生率(8.00%)低于对照组(40.00%),差异有统计学意义(P<0.05)。结论:阿托伐他汀可以协同增强阿贝西利联合氟维司群治疗HR+/HER2-型晚期乳腺癌的疗效,降低肿瘤标志物水平,减少不良反应的产生。Objective:To investigate the clinical significance of Atorvastatin combined with Abemaciclib and Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor-2-negative(HR+/HER2-)type advanced breast cancer.Method:A total of 75 patients with HR+/HER2-type advanced breast cancer admitted to Jiujiang NO.1 People's Hospital from January 2022 to August 2023 were selected as research objects and randomly divided into control group,test group A and test group B,with 25 cases in each group.The control group was treated with placebo plus Abemaciclib combined with Fulvestrant,and test group A and test group B were treated with Atorvastatin plus Abemaciclib combined with Fulvestrant,including Atorvastatin 10 mg/time in test group A and Atorvastatin 20 mg/time in test group B,for a total of 6 treatment cycles.The clinical efficacy,the levels of tumor marker carcinoembryonic antigen(CEA)and breast cancer-associated antigen 153(CA153),blood lipid indexes before treatment and after 2,4 and 6 cycles of treatment and the occurrence of adverse reactions among three groups were compared.Result:The clinical effect of the three groups was compared,the difference was statistically significant(P<0.05).The clinical effective rate of test group A and test group B were higher than that of control group(P<0.05).The differences of CEA and CA153 levels in time and inter-group effects were statistically significant(P<0.05),and there was an interaction between time and groups(P<0.05).After 2,4 and 6 cycles of treatment,CEA and CA153 in test group A and test group B were lower than those in control group,and those in test group B were lower than those in test group A,with statistical significance(P<0.05).The levels of total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C)and high density lipoprotein cholesterol(HDL-C)were statistically significant in time and inter-group effects(P<0.05),and HDL-C level had interaction between time and group(P<0.05).The HDL-C level of test group A a

关 键 词：晚期乳腺癌 阿托伐他汀 阿贝西利 氟维司群 肿瘤标志物 血脂水平 

分 类 号：R737.9[医药卫生—肿瘤]